Eptinezumab (ALD-403) is a human monoclonal antibody targeting the alpha and beta subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine[1].
Molecular Weight:
(143.36 kDa)
Purity:
99.90
CAS Number:
[1644539-04-7]
Target:
CGRP Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
